Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial
- Resource Type
- Authors
- Bharucha, KN; Brunner, HI; Penades, IC; Nikishina, I; Rubio-Perez, N; Oliveira, S; Kobusinska, K; Schmeling, H; Sztajnbok, F; Weller-Heinemann, F; Zholobova, E; Zulian, F; Allen, R; Chaitow, J; Frane, J; Wells, C; Ruperto, N; De Benedetti, F; Paediat Rheumatol Int Trials Org; Pediat Rheumatology Collaborative
- Source
- JOURNAL OF RHEUMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
- Subject
- INTERLEUKINS
BIOLOGICAL THERAPY
GROWTH
JUVENILE IDIOPATHIC ARTHRITIS
- Language
- ISSN
- 0315-162X
Objective. Evaluate growth in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with tocilizumab (TCZ) for up to 2 years in a phase III trial. Methods. Patients with pcJIA lasting at least 6 months and inadequate response to methotrexate received open-label TCZ intravenously every 4 weeks (randomly assigned to 8 or 10 mg/kg if they weighed = 30 kg) for 16 weeks. Patients with JIA American College of Rheumatology 30 response at Week 16 were randomly assigned to TCZ or placebo for 24 weeks, with an open-label extension through Week 104. Mean +/- SD height velocity (cm/yr) and World Health Organization (WHO) height SD score (SDS) were measured in patients receiving >= 1 dose of TCZ who did not receive growth hormone and in patients whose baseline Tanner stage was